Technical Analysis for APTO - Aptose Biosciences, Inc.

Grade Last Price % Change Price Change
grade D 2.03 2.53% 0.05
APTO closed up 2.53 percent on Friday, May 24, 2019, on 59 percent of normal volume. It ran into resistance at its 50 day moving average. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Flat Flat
See historical APTO trend table...

Date Alert Name Type % Chg
50 DMA Resistance Bearish 0.00%
Stochastic Buy Signal Bullish 0.00%
Outside Day Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
Oversold Stochastic Weakness 2.53%
Narrow Range Bar Range Contraction 2.53%
NR7 Range Contraction 2.53%
Stochastic Reached Oversold Weakness 2.53%
Down 3 Days in a Row Weakness 2.53%
Oversold Stochastic Weakness 2.53%

Older signals for APTO ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Aptose Biosciences Inc., a biopharmaceutical company, is engaged in the discovery, research, and development of novel anticancer therapies in Canada. The company's pipeline of cancer drug candidates includes small molecule therapies and immunotherapy. Its lead program, LOR-253, an anticancer agent, which has completed Phase I clinical trail for the treatment of solid tumors, as well as undergoing Phase II clinical trials for the treatment of relapsed/refractory hematologic malignancies. The company's discovery stage products include LOR-500, a MELK Inhibitor for Oncology, as well as small molecule programs. The company is also developing RNA-targeted therapies, including LOR-2040, an antisense ribonucleotide reductase (R2) synthesis inhibitor, which is in Phase III clinical trial for the treatment of acute myeloid leukemia; and Virulizin, a novel immunotherapy agent that has completed three Phase I/II clinical studies in solid tumors and pancreatic cancers, as well as completed a randomized placebo-controlled Phase III clinical trial for the treatment of pancreatic cancer in combination with gemcitabine. In addition, its preclinical stage products comprise LOR-220, a novel small molecule for drug-resistant bacterial infections; and IL-17E1, an immuno-modulator for oncology. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Toronto, Canada.
Medicine Biopharmaceutical Cancer Clinical Medicine Drugs Immunotherapy Oncology Solid Tumors Acute Myeloid Leukemia Pancreatic Cancer Targeted Therapy Bemcentinib Phosphoinositide 3 Kinase Inhibitor Treatment Of Acute Myeloid Leukemia Preclinical Stage Products Treatment Of Pancreatic Cancer Anticancer Therapies Pancreatic Cancers Small Molecule Therapies
Is APTO a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 2 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 4.55
52 Week Low 1.57
Average Volume 229,169
200-Day Moving Average 2.2188
50-Day Moving Average 2.036
20-Day Moving Average 2.0795
10-Day Moving Average 2.023
Average True Range 0.1005
ADX 15.83
+DI 23.0879
-DI 19.8322
Chandelier Exit (Long, 3 ATRs ) 2.0685
Chandelier Exit (Short, 3 ATRs ) 2.1615
Upper Bollinger Band 2.2955
Lower Bollinger Band 1.8635
Percent B (%b) 0.39
BandWidth 20.774225
MACD Line 0.0015
MACD Signal Line 0.0185
MACD Histogram -0.0171
Fundamentals Value
Market Cap 48.78 Million
Num Shares 24 Million
EPS -0.78
Price-to-Earnings (P/E) Ratio -2.60
Price-to-Sales 0.00
Price-to-Book 2.86
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.20
Resistance 3 (R3) 2.18 2.12 2.17
Resistance 2 (R2) 2.12 2.07 2.12 2.16
Resistance 1 (R1) 2.07 2.05 2.10 2.09 2.15
Pivot Point 2.01 2.01 2.02 2.01 2.01
Support 1 (S1) 1.96 1.96 1.99 1.98 1.91
Support 2 (S2) 1.90 1.94 1.90 1.90
Support 3 (S3) 1.85 1.90 1.89
Support 4 (S4) 1.87